CHEK1 and B-cell non-Hodgkin lymphoma: We have recently demonstrated that MCL cells are extremely sensitive to the Chk1 inhibitor PF-004777736 as single agent, much more than other B cell lymphoma cell lines and different epithelial carcinoma cell lines [21, 24].